Evidence map›Paper›PMID 32175644›Full record

ArticleJournal of clinical hypertension (Greenwich, Conn.)2020

Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib.

Syed O Amin, Marcel Ruzicka, Kevin D Burns, Isabelle A Bence-Bruckler, Stephen E Ryan, Adnan Hadziomerovic, Swapnil Hiremath

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical hypertension (Greenwich, Conn.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib.Journal of clinical hypertension (Greenwich, Conn.) · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Syed O AminDivision of Nephrology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
Marcel RuzickaDivision of Nephrology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
Kevin D BurnsDivision of Nephrology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
Isabelle A Bence-BrucklerDivision of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
Stephen E RyanDivision of Vascular/Interventional Radiology, Department of Medical Imaging, University of Ottawa, Ottawa, ON, Canada.
Adnan HadziomerovicDivision of Vascular/Interventional Radiology, Department of Medical Imaging, University of Ottawa, Ottawa, ON, Canada.
Swapnil HiremathDivision of Nephrology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.ORCID 0000-0003-0010-3416
University of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced hypertension is one of the commonest causes of secondary hypertension. In the last few years, secondary hypertension due to tyrosine kinase inhibitors, from the vascular endothelial growth factor class, has been recognized to be an important cause of hypertension, as well as proteinuria, and occasionally kidney dysfunction in some cases. Less well-recognized is that BCR-ABL tyrosine kinase inhibitors also have adverse vascular effects. These manifest as vascular stenoses in large vessels, which may sometimes cause renal artery stenosis and subsequent hypertension. We describe a case report which presented as classical bilateral renal artery stenosis, and responded to revascularization. Increased awareness of these effects, as well as research into the pathogenesis, may provide more insight into vascular biology.

Indexed as

Hypertension, RenovascularLeukemia, Myelogenous, Chronic, BCR-ABL PositiveDrug Resistance, NeoplasmFusion Proteins, bcr-ablHumansImidazolesProtein Kinase InhibitorsPyridazinesVascular Endothelial Growth Factor AFusion Proteins, bcr-ablImidazolesponatinibProtein Kinase InhibitorsPyridazinesVascular Endothelial Growth Factor ABCR-ABL mutationdrug-induced hypertensionhypertensionrenovascular hypertensiontyrosine kinase inhibitors

Identifiers

PMID32175644
PMCPMC8029973
OpenAlexW3011063776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.